Cabaletta Bio Inc (CABA)

NASDAQ
0.650
+0.020(+3.19%)
After Hours
0.650
0.000(-0.031%)
- Real-time Data
  • Volume:
    280,658
  • Day's Range:
    0.637 - 0.675
  • 52 wk Range:
    0.590 - 14.950

CABA Overview

Prev. Close
0.63
Day's Range
0.637-0.675
Revenue
-
Open
0.667
52 wk Range
0.59-14.95
EPS
-1.83
Volume
280,658
Market Cap
18.86M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,343,587
P/E Ratio
-0.482
Beta
1.58
1-Year Change
-94.65%
Shares Outstanding
29,013,995
Next Earnings Date
Nov 15, 2022
What is your sentiment on Cabaletta Bio?
or
Market is currently closed. Voting is open during market hours.

Cabaletta Bio Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Cabaletta Bio Inc Company Profile

Cabaletta Bio Inc Company Profile

Employees
54

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company’s lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Read More

Analyst Price Target

Average12.500 (+1823.08% Upside)
High17
Low8
Price0.65
No. of Analysts6
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellStrong Sell
Technical IndicatorsStrong SellStrong SellBuyStrong SellStrong Sell
SummaryStrong SellStrong SellNeutralStrong SellStrong Sell